Published in final edited form as:

Curr Opin Anaesthesiol. 2017 June ; 30(3): 349–356. doi:10.1097/ACO.0000000000000455.

Codeine and Opioid Metabolism – Implications and Alternatives for Pediatric Pain Management

Vidya Chidambaran, M.D. [Associate Professor of Clinical Anesthesia and Pediatrics],
Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, University of
Cincinnati, 3333 Burnet Ave, Cincinnati, OH 45229

Senthilkumar Sadhasivam, M.D. [Professor of Clinical Anesthesia and Pediatrics], and
Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, University of
Cincinnati, 3333 Burnet Ave, Cincinnati, OH 45229

Mohamed Mahmoud, M.D. [Associate Professor of Clinical Anesthesia and Pediatrics]
Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, University of
Cincinnati, 3333 Burnet Ave, Cincinnati, OH 45229

Abstract

Purpose of review—Use of perioperative opioids for surgical pain management of children presents clinical challenges because of concerns of serious adverse effects including life-threatening respiratory depression. This is especially true for children with history of obstructive sleep apnea. This review will explore current knowledge of clinically relevant factors and genetic polymorphisms that affect opioid metabolism and postoperative outcomes in children.

Recent findings—Within the past several years, an increasing number of case reports have illustrated clinically important respiratory depression, anoxic brain injuries and even death among children receiving appropriate weight-based dosages of codeine and other opioids for analgesia at home setting particularly following tonsillectomy. Several national and international organizations have issued advisories on use of codeine in pediatrics, based on *CYP2D6* pharmacogenetics. We have discussed the pros and cons of alternatives to codeine for pain management.

Summary—Although routine preoperative genotyping to identify children at risk and personalized opioid use for pediatric perioperative pain management is still a distant reality, current known implications of *CYP2D6* pharmacogenetics on codeine use shows that pharmacogenetics has the potential to guide anesthesia providers on perioperative opioid selection and dosing to maximize efficacy and safety.

Keywords

Analgesia; anesthesia; obstructive sleep apnea syndrome; opioids; Codeine; Pharmacogenetics; pharmacogenomics; polymorphism

Corresponding Author and Address: Mohamed Mahmoud, MD, Associate Professor in Clinical Anesthesia and Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, MLC 2001, Cincinnati, OH 45229, Phone: 513-636-4408, Fax: 513-636-7337, mohamed.mahmoud@cchmc.org.

The authors have no financial disclosures.

Conflicts of interest: Authors have no conflicts of interest.

Introduction

Respiratory depression is the most serious adverse effect of opioids as it could potentially lead to hypoxic brain injury and fatality (1). Opioids are responsible for fifty percent of postoperative respiratory failure events (2, 3). Unpredictable large inter-patient variations in opioid responses and narrow therapeutic indices of opioids result in a high incidence of postoperative opioid related respiratory depression (up to 41%) (4, 5), especially in children who are sensitive to opioids and differ in physiology and pharmacology from adults (6). A national survey (data from 252 institutions) of Patient/Proxy Controlled Analgesia (PCA) practices in children <6 years reported 8 deaths and 42 respiratory depressant incidents requiring naloxone over 5 years (7). A review of the LexisNexis database (1984-2010) for deaths and complications following tonsillectomy showed that 18% of death and 8.6% of injury claims (mainly anoxic brain injury) in children are opioid related (8). While various patient risk factors for in-hospital opioid induced respiratory children in children have been described, including age <1 year, obstructive sleep apnea (OSA), obesity, being underweight, prematurity, and developmental delay (9), twin studies have also revealed significant heritability (30%) for respiratory depression from opioids (10). In fact, in pediatrics, there has recently been multiple fatalities in children from the use of codeine which has turned our attention to the role of genetics, especially Cytochrome P450 family 2 subfamily D type 6 (*CYP2D6*) and OSA in this regard (11), (12). In this review, we will discuss briefly the role of pharmacogenetics with respect to opioid induced respiratory depression, highlighting the implications of *CYP2D6* genetics on codeine safety, pros and cons of alternatives to codeine, and the role of OSA as a major risk factor for opioid induced respiratory depression.

Codeine and *CYP2D6*

A) Codeine Metabolism—Codeine is a weak opioid that was endorsed by the World Health Organization as the second step on the analgesic ladder for cancer pain and has been used routinely for postoperative and for breakthrough pain in chronic sufferers. It is a pro-drug with a 200-fold weaker affinity for μ -opioid receptors than morphine; while 80% of the administered drug is inactivated by glucuronidation to codeine-6-glucuronide by uridine 5'-diphosphate glucuronosyltransferase-2B7 (*UGT2B7*) and *N*-demethylation to norcodeine by *CYP3A4*, 5-10% of codeine undergoes O-demethylation to morphine, its active form via *CYP2D6*.(13) (Figure) Without O-demethylation, codeine confers a small fraction of the analgesic potency of morphine, and much of its analgesic effect is likely contributed by a metabolite, codeine 6-glucuronide.(14)

B) Codeine Use in Pediatrics—Codeine with and without acetaminophen has been a commonly prescribed medicine for pain (>18 million US outpatient prescriptions in 2013) (15) as it is relatively inexpensive, widely available in both liquid and tablet form and was considered to be tolerated well. In fact, a study from 2011 reported that codeine was prescribed to >800 000 patients less than 11 years of age, more than any other opioid(16). Codeine was mostly prescribed by otolaryngologists (19.6%), dentists (13.3%), pediatricians (12.7%), and general practice/family physicians (10.1%). Hydrocodone-containing analgesics were recent rescheduled from the Drug Enforcement Administration (DEA)

Schedule III to the more tightly regulated Schedule II. This left codeine coformulated with acetaminophen as the only opioid analgesic classified as a Schedule III controlled substance and cough formulations with codeine remain Schedule V under federal law(17); unlike their Schedule II counterparts, Schedule III regulations allow for verbal and facsimile prescribing to pharmacies as well as refills with the original prescription. However, reports of fatalities in children from the use of codeine (18, 19) have raised concerns about the safety of codeine use (20-22). This was emphasized by the American Academy of Pediatrics recently in a report released recently titled “Codeine: Time to Say “No”.(12)

C) *CYP2D6* polymorphisms and Phenotypes—Variability in the clinical response to codeine prompted investigations into genetic variants or polymorphisms of *CYP2D6*. This enzyme is mapped to chromosome 22 at 22q13.1. More than 100 polymorphisms (functional and nonfunctional) of *CYP2D6* have been described to date (<http://www.cypalleles.ki.se/cyp2d6.htm>) (23). *CYP2D6**1 is the wild-type allele and is associated with normal enzyme activity and the “extensive metabolizer” (EM) phenotype. The *CYP2D6* alleles *2, *33, and *35 are also considered to have near-normal activity.

The mutant alleles, *3, *4, *5, *6, and *9, confer no *CYP2D6* activity (23-25) and account for more than 90% of poor metabolizer phenotypes. Variants *10, *17 and *41 have modestly reduced activity and are referred as intermediate metabolizers (IM) (25). An individual who has multiple copies of functional genes(24), would have the Ultrarapid metabolizer (UM) phenotype. Genetic testing is commonly available for common *CYP2D6* variants. An activity score is assigned to each allele in the diplotype (0 for nonfunctional, 0.5 for reduced function, and 1 for each copy of a functional allele). The patient's predicted metabolizer phenotype, is defined by the sum of the two scores:

- PM has an activity score of 0
- IM has an activity score of 0.5
- EM (normal) has an activity score of 1 to 2
- UM has an activity score greater than 2

There are inter-ethnic differences in frequency of these phenotypes; while 10% of Caucasians and 30% of Hong Kong Chinese are PM(25), 1% in Denmark and Finland, 10% in Greece and Portugal and 29% in Ethiopia(26) are UM. Hence, while codeine may be less effective as an analgesic in about 2-10% of ethnic groups (27, 28), it could be a dangerous analgesic in the latter populations, as excessive doses of morphine may be rapidly produced (25).

D) Reports of Codeine fatalities—Several deaths or near deaths have been reported with “standard” doses of oral codeine in children later found to be UM of *CYP2D6* (18, 29). In 2009, a fatality after codeine administration was reported in a healthy 2-year old boy given codeine two days after adenotonsillectomy. Autopsy results showed high blood concentrations of morphine (32 ng/mL) and low codeine concentrations (0.70 ng/mL); genotyping revealed functional duplication of the *CYP2D6* allele.(18) This was followed by further reports in 2012, of three deaths and two cases of respiratory insufficiency in post-

surgical children, who had risk factors like OSA (19, 30). In 2013, obesity, codeine toxicity and polypharmacology were implicated in the deaths of three obese children aged four to 10 years given codeine doses based on ideal body weight(31).

E) Regulations against Codeine Use in Pediatrics and Breast-feeding Mothers

—These incidents ultimately led to new regulations by the World Health Organization (March 2011)(32), US Food and Drug Administration (FDA) (August 2012)(33), European Medicines Agency (EMA)(34) and Health Canada (June 2013)(35) and the UK Medicines and Healthcare Products Regulatory Agency (July 2013 updated in April 2015)(36). Restrictions were placed on use of codeine in children under the age of 12 years, after adenotonsillectomy procedures.(37) In 2013, the joint FDA advisory committee recommended amendment of the codeine label to include a “black box warning” contraindicating codeine treatment of pain and cough in all children <18 years of age and to remove codeine from the Over-the-Counter monograph.(38) The “Warnings/sections of the label were also updated.

A recent review of the adverse event reporting systems data of children who had codeine or codeine-containing products by the FDA over past 50 years showed 64 cases of severe respiratory depression and 24 deaths mostly in children younger than 12 years of age(39).

The 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for *CYP2D6* genotype and codeine therapy(40) suggest using alternative analgesics to codeine in patients who are *CYP2D6* poor for better efficacy and ultrarapid metabolizers for safety reasons. In fact, several pediatric hospitals have elected to remove codeine from their formularies.

Alternatives to Codeine

A) Non-opioid drugs—Acetaminophen and nonsteroidal anti-inflammatory drugs are good alternatives for treating mild pain, as they do not have the adverse effects of respiratory depression. Increased use of non-opioids like oral and intravenous formulations of acetaminophen and non-steroidal anti-inflammatory drugs, which do not have the respiratory depressant side effects may be good alternatives to codeine in children. Ibuprofen was found to be least as effective as acetaminophen with codeine for postoperative pain control in children after tonsillectomy and facial surgery, with no increased risks of bleeding (41-43).

Dexmedetomidine (DEX) sedation is a promising sedative agent and an adjunct to anesthetic regimen especially in patients with history of obstructive sleep apnea (OSA) (44, 45). Because of the increased risks with opioids in obese patients and those with OSA, DEX as an adjunct to anesthetic regimen may potentiate opioid analgesia with minimal additional respiratory depression. In comparison with fentanyl (1 mcg/kg), intraoperative DEX (2 mcg/kg bolus followed by 0.7 mcg /kg/hour) decreased the postoperative opioid requirements and the episodes of desaturation in children with OSA following tonsillectomy and adenoidectomy (46).

B) Tramadol—Is tramadol an alternative? Tramadol is a weak opioid agonist that is metabolized primarily through hepatic N-demethylation by *CYP3A4* to an inactive

metabolite, and minimally through *CYP2D6*-mediated oxidation to O-desmethyltramadol (M1), which has a 200-fold greater affinity for μ -opioid receptors than the parent drug.(47) Tramadol exerts its analgesic activity through complementary mechanisms: activating the μ -opioid receptor by mainly M1, and weak inhibition of norepinephrine and serotonin reuptake. A prospective, double-blinded, randomized controlled trial in children undergoing tonsillectomy compared the efficacy and safety of tramadol versus codeine/acetaminophen. The authors found that tramadol achieved similar analgesia, with less potential for side effects (48). However, studies have shown that children who are *CYP2D6*PM have lower plasma concentrations of the active metabolite and analgesia compared to EM, and in 2D6 UM, plasma concentrations, analgesia and side effects are greater than in those who are EM (49-51). There was also a recent case report of tramadol administration leading to respiratory depression in a child who was a *CYP2D6*UM (52). In fact, the 2010 FDA drug label reads that “concomitant administration of *CYP2D6* and/or *CYP3A4* inhibitors, such as quinidine, fluoxetine, paroxetine and amitriptyline (*CYP2D6* inhibitors), and ketoconazole and erythromycin (*CYP3A4* inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome”. Hence, its safety needs to be further investigated before widespread use.

C) Tapentadol—A similar agent, tapentadol, is a centrally acting analgesic with a dual mode of action as an agonist at the μ -opioid receptor and a weak norepinephrine reuptake inhibitor (compared to tramadol). It has no active metabolites and mainly undergoes glucuronidation (53). A report from a poison control center reported two patients - 9-month-old child who had coma and respiratory depression, and a 16-month-old girl with dyspnea, drowsiness/lethargy, pallor, and vomiting who was admitted to critical care and treated with oxygen. However pediatric data on the safety of this medicine is limited.

D) Oxycodone—Would oxycodone, a semisynthetic opioid, be a safer alternative to codeine for managing post-tonsillectomy pain at home setting? We know that 80% of oxycodone undergoes N-demethylation by *CYP3A* producing noroxycodone, a metabolite with weak analgesic properties; and 10% undergoes O-demethylation to oxymorphone and noroxymorphone, by *CYP2D6* (54). Oxymorphone is 14 times more potent than oxycodone (55). The affinity of noroxymorphone at the opioid receptor is three- and 10-fold higher than oxycodone and noroxycodone respectively. Hence, in order of highest to lowest potency of oxycodone and metabolites, we have oxymorphone > morphine > noroxymorphone > oxycodone > noroxycodone (56). In a postoperative setting, the *CYP2D6*PM were found to have decreased oxycodone metabolism, and higher analgesic consumption (57). The greatest oxymorphone/oxycodone concentration ratios occurred in those who are UM and smallest in those who are PM (58). Other adult studies in postsurgical patients and cancer patients detected clinical differences among the *CYP2D6* genotypes (59, 60). *CYP2D6* activity also correlated with oxycodone experimental pain assessment, with UM experiencing increased pharmacodynamic effects (61). Oxycodone overdose by wrong dosing has been reported before (62). Interestingly, *CYP2D6**4 allele (PM) implicated in the death of four fatalities from oxycodone, by a retrospective analysis of 15 cases from the Milwaukee County Medical Examiner's Office using pharmacogenomics for postmortem forensic toxicology(63). However, our ongoing pediatric oxycodone pharmacokinetic and

pharmacogenetic study in perioperative setting revealed that compared to PMs, IMs and EMs have higher oxycodone concentration. Further large studies are needed to assess whether oxycodone would be safer than codeine in children with *CYP2D6* UM metabolizing status and/or with significant sleep apnea. It has also been shown that like codeine, maternal oxycodone use also causes central nervous system depression in neonates, so oxycodone is unlikely to be a safer alternative in this clinical setting (64).

E) Hydrocodone—Hydrocodone is also a potential alternative for analgesia. It is about 12 times more potent at the opioid receptor than codeine(55), and about half the clearance is via *CYP2D6* and *CYP3A4*, into an active metabolite hydromorphone, and norhydrocodone, respectively. *CYP2D6* UM may thus have up to an eightfold greater plasma concentration of hydromorphone, whereas PM receive minimal analgesia (65). A common component of antitussive medications, the US FDA banned the sale of more than 200 hydrocodone products in response to occurrence of >400 cases of adverse events associated with its use between 1969 and 2005 (66).

Hence, although both hydrocodone and oxycodone undergo metabolism via *CYP2D6* to active metabolites, their analgesic effects are not as variable as codeine's because the parent drugs are nor prodrugs, but themselves pharmacologically active. One case report demonstrates the complex interplay between drug-drug interactions and pharmacogenomics. A developmentally delayed five year Somalian old child died after administration of high doses of hydrocodone for ear infection. On genotyping, she was found to be a *CYP2D6* PM, and had low hydromorphone blood concentrations; but co-administration of clarithromycin (a potent *CYP3A4* inhibitor) and valproic acid for seizures since birth, prevented hydrocodone metabolism leading to high hydrocodone levels(67). Hence, the dose–toxicity relationship of the alternative opioids need to be further studied in the pediatric population.

F) Oral Morphine—Lastly, the use of an oral morphine elixir has been suggested by some as an alternative(68). The prescribers and pharmacists need to be vigilant when prescribing oral morphine as it is available in many concentrations (69), however, although there is extensive experience with intravenous morphine in children, there is little clinical experience and very limited comparative clinical data on safety and efficacy available for the oral formulation.

In summary, drugs such as morphine (0.2-0.5 mg/kg/dose, every four to six hours), oxycodone (0.05-0.15 mg/kg/dose, every four to six hours), hydrocodone (0.1-0.2 mg/kg/dose, every six to eight hours) on as needed basis for severe pain are likely alternatives for severe postoperative pain, but have their disadvantages. (21).

Managing post-tonsillectomy pain safely and effectively without Codeine at home

Pediatric OSA is associated with high incidences of adverse outcomes with the use of opioid analgesics for post-tonsillectomy pain management. In addition to codeine, potentially other oral opioids metabolized by the *CYP2D6* pathway such as tramadol, hydrocodone and even oxycodone, cannot be considered safe analgesics without appropriate precautions to manage post-tonsillectomy pain at unmonitored home setting especially in young children with sleep apnea. (64)

Though preoperative *CYP2D6* genotyping study in children undergoing tonsillectomy is an option, it is not widely available and third party payers do not readily reimburse for the genetic tests despite the CPIC guidelines (40) and other evidences, we observed significantly more adverse effects with codeine at home even when it was administered on as needed basis (Unpublished Data: Sadhasivam, MD 2012). Preoperative *CYP2D6* testing before prescribing around the clock codeine, hydrocodone, tramadol and oxycodone at home setting would be preferable as all are at least partially metabolized by *CYP2D6* pathway (Figure), especially in young children with OSA and other respiratory comorbidities. Alternatively, using other analgesics (i.e. non-opioids and possibly oral morphine with appropriate doses) will lead to safer outcomes following tonsillectomy in young children.

Cincinnati Children's Hospital Medical Center Pain Management Protocol after tonsillectomy

An alternative and less expensive approach to routine preoperative *CYP2D6* genotyping would be to use safer and non-opioid analgesics in young children.(70) In our institution, we changed our tonsillectomy practice (in children < 6 years) even before the 2013 FDA's warning based on many reported and unreported deaths related to opioid pharmacogenetics (71, 72) and based on our prospective pharmacogenetic research in children undergoing tonsillectomy and receiving morphine in the hospital and codeine at home. To maximize pain relief and safety, we have successfully used opioid sparing pain management at home setting following pediatric tonsillectomy. Our current practice is summarized in Table 1. We avoid all oral opioids at home setting on the day of tonsillectomy because of reports of high incidences of respiratory depression and deaths in the evening/night after tonsillectomy (69, 73). Despite our high annual volume of tonsillectomy, we have not seen any increase in incidence of inadequate pain control, postoperative bleeding or serious life threatening complications with the above pain management regimen in the last 3 years.

Future directions of research

Currently, robust evidence to change clinical practice based on underlying genetic risk factors, access to routine preoperative genotyping, affordability and payer coverage for genetic testing are limited. As compelling evidence for personalization of perioperative care based on genetic risk factors (e.g. *CYP2D6* and codeine related deaths) increases, there will be better adaptability of routine preoperative genotyping and coverage of such services by third party payers. For example, many third-party payers are covering perioperative *CYP2D6* genotyping for prescription of oral opioids in our pediatric institution. In future, pharmacogenetic studies also need to be complimented by epigenetic, proteomic, transcriptomic, and metabolomic information to gain additional knowledge and insight to improving personalized care as these factors may influence clinical outcome measures. Another need of pharmacogenomics research, especially in pediatrics, is genetic counseling. Genetic counselors help patients and their families understand and adapt to the medical, psychological, and familial implications of genetic contributions to clinical outcomes. As we transition from single-gene testing and genetic counseling to a full genomic medicine approach, clinical implications will get more complex.(74)

Clinical Translation: Bench to Bedside

As we routinely use the Global Positioning System to navigate maps and roads, in the future, it is anticipated that we will use a Genomic Prescribing System (GPS) to proactively identify underlying genetic risks and guide personalized care.(75) Proactive identification of patients at risk of adverse perioperative outcomes is an important first step in guiding personalized interventions with preferably Electronic Health Record (EHR) implemented clinical decision support integrating genetic risk factors and their implications for clinical interventions.

To implement pharmacogenomic based clinical decision support, there is a need for more robust study designs, independent validations, larger populations and robust statistical approaches.(76, 77) To realize the promise of personalized medicine to perioperative care, we need better evidences in terms of validating clinical association studies engaging physicians, patients, pharmaceutical industry, healthcare payers and policy makers. Others have taken a more active stance by identifying the 2D6 isoforms in their patients. For example, pharmacogenetic data gathered under the “Pharmacogenetics for kids” trial was incorporated into clinical decision support tools for the prescription of opioids in children with sickle cell disease (78).

Conclusion

Current known implications of CYP2D6 pharmacogenetics on codeine use shows that pharmacogenetics has the potential to guide anesthesiologists on perioperative opioid selection and dosing to maximize efficacy and safety. The present consensus seems to be that avoiding codeine whenever possible is the safest strategy. Currently, personalized opioid selection and dosing for perioperative pain management is still a long way. More studies are needed to improve genotype-based personalized perioperative care in children.

Acknowledgments

None

Financial support and sponsorship: This work was supported in part by the from The project described was supported by the 1 R01 HD089458 through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

References

1. Lotsch J, Dudziak R, Freynhagen R, Marschner J, Geisslinger G. Fatal respiratory depression after multiple intravenous morphine injections. *Clinical pharmacokinetics*. 2006; 45(11):1051–60. [PubMed: 17048971]
2. Overdyk FJ. Postoperative opioids remain a serious patient safety threat. *Anesthesiology*. 2010; 113(1):259–60. [PubMed: 20574235]
3. Fecho K, Jackson F, Smith F, Overdyk FJ. In-hospital resuscitation: opioids and other factors influencing survival. *Therapeutics and clinical risk management*. 2009; 5:961–8. [PubMed: 20057895]
4. Voepel-Lewis T, Marinkovic A, Kostrzewa A, Tait AR, Malviya S. The prevalence of and risk factors for adverse events in children receiving patient-controlled analgesia by proxy or patient-controlled analgesia after surgery. *Anesth Analg*. 2008; 107(1):70–5. [PubMed: 18635469]

5. Overdyk FJ, Carter R, Maddox RR, Callura J, Herrin AE, Henriquez C. Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient-controlled analgesia. *Anesth Analg*. 2007; 105(2):412–8. [PubMed: 17646499]
6. Duarte LT, Fernandes Mdo C, Costa VV, Saraiva RA. [The incidence of postoperative respiratory depression in patients undergoing intravenous or epidural analgesia with opioids]. *Revista brasileira de anesthesiologia*. 2009; 59(4):409–20. [PubMed: 19669015]
7. Nelson KL, Yaster M, Kost-Byerly S, Monitto CL. A national survey of American Pediatric Anesthesiologists: patient-controlled analgesia and other intravenous opioid therapies in pediatric acute pain management. *Anesth Analg*. 2010; 110(3):754–60. [PubMed: 20185654]
8. Stevenson AN, Myer CM 3rd, Shuler MD, Singer PS. Complications and legal outcomes of tonsillectomy malpractice claims. *The Laryngoscope*. 2012; 122(1):71–4. [PubMed: 22076638]
9. Chidambaran V, Olbrecht V, Hossain M, Sadhasivam S, Rose J, Meyer MJ. Risk predictors of opioid-induced critical respiratory events in children: naloxone use as a quality measure of opioid safety. *Pain Med*. 2014; 15(12):2139–49. [PubMed: 25319840]
10. Angst MS, Lazzaroni LC, Phillips NG, Drover DR, Tingle M, Ray A, et al. Aversive and reinforcing opioid effects: a pharmacogenomic twin study. *Anesthesiology*. 2012; 117(1):22–37. [PubMed: 22713632]
11. Niesters M, Overdyk F, Smith T, Aarts L, Dahan A. Opioid-induced respiratory depression in paediatrics: a review of case reports. *Br J Anaesth*. 2013; 110(2):175–82. [PubMed: 23248093]
- 12*. Tobias JD, Green TP, Cote CJ, Section On A, Pain M, Committee On D. Codeine: Time To Say “No”. *Pediatrics*. 2016 This article describes the CYP2D6 pharmacogenetic implications for the use of codeine with a discussion on the pros and cons of using codeine in pediatrics.
13. Vree TB, Verwey-van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. *Biopharm Drug Dispos*. 1992; 13(6):445–60. [PubMed: 1391681]
14. Lotsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, et al. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. *Clin Pharmacol Ther*. 2006; 79(1):35–48. [PubMed: 16413240]
- 15*. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Annu Rev Pharmacol Toxicol*. 2015; 55:89–106. This article describes the common elements among programs that have implemented preemptive genotyping and highlights key processes for implementation, including clinical decision support. [PubMed: 25292429]
16. Cartabuke RS, Tobias JD, Taghon T, Rice J. Current practices regarding codeine administration among pediatricians and pediatric subspecialists. *Clin Pediatr (Phila)*. 2014; 53(1):26–30. [PubMed: 23922249]
17. Controlled Substances - by CSA schedule, (2016).
18. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. *N Engl J Med*. 2009; 361(8):827–8. [PubMed: 19692698]
19. Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, et al. More codeine fatalities after tonsillectomy in North American children. *Pediatrics*. 2012; 129(5):e1343–7. [PubMed: 22492761]
20. Fleming ML, Wanat MA. To prescribe codeine or not to prescribe codeine? *J Pain Palliat Care Pharmacother*. 2014; 28(3):251–4. [PubMed: 25102040]
21. Galinkin JL. It's time to rethink use of codeine in pediatric patients. *AAP News*. 2011
22. Tremlett M, Anderson BJ, Wolf A. Pro-con debate: is codeine a drug that still has a useful role in pediatric practice? *Paediatr Anaesth*. 2010; 20(2):183–94. [PubMed: 20059720]
23. Palmer SN, Giesecke NM, Body SC, Shernan SK, Fox AA, Collard CD. Pharmacogenetics of anesthetic and analgesic agents. *Anesthesiology*. 2005; 102(3):663–71. [PubMed: 15731608]
24. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. *Annu Rev Med*. 2006; 57:119–37. [PubMed: 16409140]
25. Williams DG, Hatch DJ, Howard RF. Codeine phosphate in paediatric medicine. *Br J Anaesth*. 2001; 86(3):413–21. [PubMed: 11573533]
26. Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. *Eur J Clin Invest*. 2003; 33(Suppl 2):17–22.

27. Arnold J, Ahsan F, Meezan E, Pillion DJ. Nasal administration of low molecular weight heparin. *J Pharm Sci.* 2002; 91(7):1707–14. [PubMed: 12115833]
28. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. *Eur J Clin Pharmacol.* 1996; 51(3-4):289–95. [PubMed: 9010701]
29. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med.* 2004; 351(27):2827–31. [PubMed: 15625333]
30. Khetani JD, Madadi P, Sommer DD, Reddy D, Sistonen J, Ross CJ, et al. Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study. *Paediatr Drugs.* 2012; 14(6):411–5. [PubMed: 23013460]
31. Friedrichsdorf SJ, Nugent AP, Strobl AQ. Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports. *J Opioid Manag.* 2013; 9(2):151–5. [PubMed: 23709324]
32. Organization, WH. Geneva, Switzerland: 2011. Unedited report of the 18th Expert Committee on the Selection and Use of Essential Medicines. Available from: http://www.who.int/selection_medicines/Complete_UNEDITED_TRS_18th.pdf
33. Administration UFaD. Rockville, MD: US Food and Drug Administration; 2012. Drug safety communication. Codeine use in certain children after tonsillectomy and or adenoidectomy may lead to rare but life threatening adverse events or death. Available from: www.fda.gov/Drugs/DrugSafety/ucm313631.htm
34. Agency, EM. London, United Kingdom: European Medicines Agency; 2013. Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_containing_medicinal_products/Position_provided_by_CMDh/WC500144850.pdf
35. Canada, H. Ottawa, Canada: Health Canada; 2013. Health Canada's review recommends codeine only be used in patients aged 12 and over. Available from: www.healthycanadians.gc.ca/recall-alert-rappel-avis/hcsc/2013/33915aeng.php
36. Agency, EM. London, United Kingdom: European Medicines Agency; 2015. Codeine not to be used in children below 12 years for cough and cold. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_cough_or_cold_in_children/Position_provided_by_CMDh/WC500186159.pdf
- 37*. Andrzejowski P, Carroll W. Codeine in paediatrics: pharmacology, prescribing and controversies. *Arch Dis Child Educ Pract Ed.* 2016; 101(3):148–51. The authors describe in detail the developmental pharmacology underpinning the action of codeine, reviewing what is known about the pharmacokinetics, pharmacodynamics and pharmacogenetics in children, how this relates to prescribing, as well as the practical issues and the recent regulatory framework surrounding its use. [PubMed: 26984558]
38. Food and Drug Administration. FDA Drug Safety Communication; 2013. Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. [Internet][cited 2013 April 23]; (2/25/2013):[<http://www.fda.gov/Drugs/DrugSafety/ucm339112.htm> p.]. Available from: <http://www.fda.gov/Drugs/DrugSafety/ucm339112.htm>
39. Food and Drug Administration; Center for Drug Evaluation and Research; 2015. Summary Minutes of the Joint Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Meeting. [Internet]Available from: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM482005.pdf>
40. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther.* 2014; 95(4):376–82. [PubMed: 24458010]
41. Charles CS, Matt BH, Hamilton MM, Katz BP. A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. *Otolaryngol Head Neck Surg.* 1997; 117(1):76–82. [PubMed: 9230328]

42. Bedwell JR, Pierce M, Levy M, Shah RK. Ibuprofen with acetaminophen for postoperative pain control following tonsillectomy does not increase emergency department utilization. *Otolaryngol Head Neck Surg.* 2014; 151(6):963–6. [PubMed: 25205639]
43. Chen T, Adamson PA. Comparison of ibuprofen and acetaminophen with codeine following cosmetic facial surgery. *J Otolaryngol Head Neck Surg.* 2009; 38(5):580–6. [PubMed: 19769830]
44. Mahmoud M, Gunter J, Donnelly LF, Wang Y, Nick TG, Sadhasivam S. A comparison of dexmedetomidine with propofol for magnetic resonance imaging sleep studies in children. *Anesth Analg.* 2009; 109(3):745–53. [PubMed: 19690241]
- 45**. Mahmoud M, Mason KP. Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations. *Br J Anaesth.* 2015; 115(2):171–82. This paper review focuses on the current Paediatric perioperative and periprocedural applications of dexmedetomidine as well as its limitations, with a consideration for the future. [PubMed: 26170346]
46. Patel A, Davidson M, Tran MC, Quraishi H, Schoenberg C, Sant M, et al. Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy. *Anesth Analg.* 2010; 111(4):1004–10. [PubMed: 20705788]
47. Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. *Regul Toxicol Pharmacol.* 2011; 59(3):385–90. [PubMed: 21215785]
48. Friedrichsdorf SJ, Postier AC, Foster LP, Lander TA, Tibesar RJ, Lu Y, et al. Tramadol versus codeine/acetaminophen after pediatric tonsillectomy: A prospective, double-blinded, randomized controlled trial. *J Opioid Manag.* 2015; 11(4):283–94. [PubMed: 26312955]
49. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. *Pain.* 2003; 105(1-2):231–8. [PubMed: 14499440]
50. Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. *Eur J Clin Pharmacol.* 2006; 62(11): 927–31. [PubMed: 16960721]
51. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. *J Clin Psychopharmacol.* 2008; 28(1):78–83. [PubMed: 18204346]
- 52**. Orliaguet G, Hamza J, Couloigner V, Denoyelle F, Lorient MA, Broly F, et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. *Pediatrics.* 2015; 135(3):e753–5. Although there are several case reports about codeine fatalities, this article presents a case of severe respiratory depression in a child, with ultrarapid CYP2D6 genotype and obstructive sleep apnea syndrome, after taking tramadol for pain relief related to a day-case tonsillectomy. [PubMed: 25647677]
53. Barbosa J, Faria J, Queiros O, Moreira R, Carvalho F, Dinis-Oliveira RJ. Comparative metabolism of tramadol and tapentadol: a toxicological perspective. *Drug Metab Rev.* 2016:1–16.
54. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. *Drug Metab Dispos.* 2004; 32(4):447–54. [PubMed: 15039299]
55. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. *Life Sci.* 1991; 48(22):2165–71. [PubMed: 1851921]
56. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. *Br J Pharmacol.* 2010; 160(4):907–18. [PubMed: 20590587]
57. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. *PLoS One.* 2013; 8(3):e60239. [PubMed: 23555934]
58. Naito T, Takashina Y, Yamamoto K, Tashiro M, Ohnishi K, Kagawa Y, et al. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. *J Clin Pharmacol.* 2011; 51(11):1529–38. [PubMed: 21209234]

59. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. *Acta Anaesthesiol Scand*. 2010; 54(2):232–40. [PubMed: 19719813]
60. Andreassen TN, Eftedal I, Klestad P, Davies A, Bjordal K, Lundstrom S, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. *Eur J Clin Pharmacol*. 2012; 68(1):55–64. [PubMed: 21735164]
61. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. *Br J Pharmacol*. 2010; 160(4):919–30. [PubMed: 20590588]
62. Boyle KL, Rosenbaum CD. Oxycodone overdose in the pediatric population: case files of the University of Massachusetts Medical Toxicology Fellowship. *J Med Toxicol*. 2014; 10(3):280–5. [PubMed: 24610706]
63. Jannetto PJ, Wong SH, Gock SB, Laleli-Sahin E, Schur BC, Jentzen JM. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. *J Anal Toxicol*. 2002; 26(7):438–47. [PubMed: 12422998]
64. Lam J, Kelly L, Ciszowski C, Landsmeer ML, Nauta M, Carleton BC, et al. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. *J Pediatr*. 2012; 160(1):33–7 e2. [PubMed: 21880331]
65. Stauble ME, Moore AW, Langman LJ, Boswell MV, Baumgartner R, McGee S, et al. Hydrocodone in postoperative personalized pain management: pro-drug or drug? *Clin Chim Acta*. 2014; 429:26–9. [PubMed: 24269714]
66. Mitka M. FDA bans sale of unapproved cough suppressants containing hydrocodone. *JAMA*. 2007; 298(19):2251–2. [PubMed: 18029822]
67. Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszowski C, Ross CJ, et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. *Pediatrics*. 2010; 126(4):e986–9. [PubMed: 20837591]
68. Anderson BJ. Is it farewell to codeine? *Arch Dis Child*. 2013; 98(12):986–8. [PubMed: 23975721]
69. Subramanyam R, Chidambaran V, Ding L, Myer CM 3rd, Sadhasivam S. Anesthesia- and opioids-related malpractice claims following tonsillectomy in USA: LexisNexis claims database 1984-2012. *Paediatr Anaesth*. 2014; 24(4):412–20. [PubMed: 24417679]
70. Sadhasivam S, Myer Iii CM. Preventing Opioid-Related Deaths in Children Undergoing Surgery. *Pain Med*. 2012 Jul; 13(7):982–3. [PubMed: 22694279]
71. Chidambaran V, Ngamprasertwong P, Vinks AA, Sadhasivam S. Pharmacogenetics and anesthetic drugs. *Curr Clin Pharmacol*. 2012; 7(2):78–101. [PubMed: 22432844]
72. Cohen M, Sadhasivam S, Vinks AA. Pharmacogenetics in perioperative medicine. *Curr Opin Anaesthesiol*. 2012; 25(4):419–27. [PubMed: 22673786]
73. Prows CA, Zhang X, Huth MM, Zhang K, Saldana SN, Daraiseh NM, et al. Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study. *The Laryngoscope*. 2014; 124(5):1242–50. [PubMed: 24122716]
74. Ormond KE. From genetic counseling to “genomic counseling”. *Mol Genet Genomic Med*. 2013; 1(4):189–93. [PubMed: 24498615]
75. Ratain MJ. Personalized medicine: building the GPS to take us there. *Clin Pharmacol Ther*. 2007; 81(3):321–2. [PubMed: 17339859]
76. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. *Int J Epidemiol*. 2008; 37(1):120–32. [PubMed: 17898028]
77. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. *Clin Pharmacol Ther*. 2008; 83(5):781–7. [PubMed: 18253145]
78. Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, et al. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. *Pediatrics*. 2016; 138(1)

Key points

- A multimodal opioid-sparing analgesia strategy reduces the need for perioperative opioid use, and improves analgesia and reduces serious risks associated with opioids in children, especially at unmonitored home setting.
- It is high time to avoid codeine and possibly other stronger opioids metabolized via *CYP2D6* pathway, especially in children with significant co-morbidities such as OSA or significant respiratory disease.
- Genetic identification of known variant alleles that affect the pharmacokinetics or pharmacodynamics of opioid agents can enable anesthesia providers to better select the appropriate opioid and dosing regimen for an individual patient, instead of empirical selection and dosing escalation. Currently, personalized opioid selection and dosing for perioperative pain management is still a long way off. More studies are needed to improve genotype-based personalized perioperative care in children.

Figure.

CYP2D6 metabolic pathway of common oral opioids resulting in biologically active metabolites. Depending on *CYP2D6* metabolic activity (poor, intermediate, extensive or ultrarapid metabolizing status) varying levels of respective active metabolites from codeine, tramadol, hydrocodone and oxycodone are formed resulting in clinically unpredictable inter-individual variations in responses. Oral morphine, hydromorphone and tapentadol are not affected by the *CYP2D6* metabolic pathway.

Table 1
Our current practice of opioid sparing pain management at home setting following pediatric tonsillectomy

Cincinnati Children's Hospital Medical Center's Standardized Post-Tonsillectomy Pain Management Protocol	
Children < 6 years	No Codeine or other opioids Acetaminophen Around the clock Dexamethasone Day of Surgery, Postoperative day #1 & 2 Ibuprofen from Postoperative day #1
Children > 6 years	Acetaminophen Around the clock Dexamethasone Day of Surgery, Postoperative day #1 & 2 Ibuprofen from Postoperative day #1 Oxycodone q4h prn from Postoperative day #1

Abbreviations: Prn = as needed basis